FIELD: medicine.
SUBSTANCE: claimed invention relates to medicine, namely to therapy and immunology, and deals with the treatment of Degos disease. For this purpose an effective quantity of a complement inhibitor is introduced in the form of monotherapy or as a part of conventional complex therapy.
EFFECT: method ensures an increase of the said disease treatment efficiency due to the reduction of complement-mediated endothelium affection.
15 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| PROLONGATION OF ALLOGRAFT SURVIVAL BY COMPLEMENT ACTIVITY INHIBITION | 2007 |
|
RU2445975C2 |
| COMPLEMENT-BINDING APTAMERS AND C5 AGENTS APPLICABLE FOR TREATING OCULAR DISORDERS | 2007 |
|
RU2477137C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2662563C2 |
| ANTIBODIES TO COMPLEMENT COMPONENT C5 | 2015 |
|
RU2693430C2 |
| HUMANIZED MODEL OF KIDNEY AND LIVER DISORDERS | 2018 |
|
RU2772583C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2718850C2 |
| MODULATION OF COMPLEMENT ACTIVITY | 2015 |
|
RU2670988C2 |
| COMPLEMENT ACTIVITY MODULATORS | 2017 |
|
RU2778811C2 |
